Abstract: This invention provides an immunomodulator for use in the treatment, reduction, inhibition or control of cancer subject, wherein the subject is clinically classified as having a performance status of 1-, 2, 3 or 4 according to the ECOG Scale, or classified as not being of an age and/or not being sufficiently fit to tolerate two or more chemotherapy regimens. The invention also describes the use of one or more additional anticancer treatments or agents as well as protocols and dosage regimens for use.

Abstract: This invention provides an immunomodulator for use in the adjuvant, neoadjuvant or peri-adjuvant treatment, reduction, inhibition or control of cancer in patients that have undergone, or are intended to undergo, tumour resection surgery and/or one or more additional anticancer treatments or agents, preferably checkpoint inhibitor therapy. The invention also describes the use of one or more additional anticancer treatments or agents in the adjuvant, neoadjuvant or peri-adjuvant setting, as well as protocols and dosage regimens for use.

Abstract: The present invention relates to the use of an immunomodulator comprising non-pathogenic non-viable Mycobacterium, such as Mycobacterium obuense (IMM-101), and one or more biologically-active agents, suitably an antigen or antigenic determinant, in a method of treating or preventing a infection and/or the symptoms associated thereof in a human subject at elevated risk of exposure to and/or severity of said infection, such as a healthcare or social care worker or cancer patient, wherein said viral infections are preferably caused by a coronavirus. The invention is particularly applicable to those infections caused by SARS-CoV, MERS-CoV, or SARS-CoV-2 (COVID-19). The invention also provides an adjuvant and pharmaceutical composition comprising said immunomodulator optionally with a pharmaceutically acceptable carrier, diluent or excipient, as well as the use of said adjuvant or said pharmaceutical composition in the manufacture of a medicament for the treatment or preventions of said infections.

Abstract: Embodiments of the present invention relate to devices and methods for detecting cellular products using detection particles having product-specific detection reagents and having a characteristic spectral feature. In particular, devices and methods are provided for measuring secreted cellular products including cytokines. Detection substrates, include microwells having product-specific capture reagents thereon or comprising hydrophobic membranes are described having greater capability to detect products from individual cells in a mixture of heterogeneous cells. With the use of multiple detection particles, multiple cellular products can be detected in a single well. Additionally, using the inherent spectral properties of detection particles, no enzymatic reactions are needed to visualize a secreted product, thereby increasing the sensitivity, reproducibility and ease of use.